Open-to-Accrual Therapeutic Trials

Gynecologic Oncology

Trials are listed from Phase 1 to Phase 3, alphabetically.  Please click on the name of the Lead Clinical Research Coordinator (CRC) to request more information about each trial.

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


TESARO 4010-01-001   NCT0275284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Kelly Jenkins Advanced solid tumors I
ADXS001-004 NCT02291055 Phase 1-2 Study of MEDI4736 Alone or In Combination With ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Metastatic Head & Neck Cancer S. Ghamande Renee Townsend  Cervical I/II
CL-PTL-126   NCT03073525 A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers S. Ghamande  Melissa James Cervical, Ovarian, and Uterine Cancer  II
D6010C00004/ GYN49   NCT02272790 A Multicentre Randomised Phase II Study of AZDl 775 plus Chemotherapy versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S. Ghamande Donna Wheatley Ovarian, Peritoneal, or Fallopian Tube Cancer II
GOG-3011/ FORWARD1   NCT02631876 A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigators Choice of Chemotherapy in Adults with Folate Receptor α-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube Cancer S.  Ghamande Renee Townsend Ovarian, Primary Peritoneal or Fallopian Tube Cancer II
Millennium C31004   NCT02725268 A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer S.  Ghamande Melissa James Endometrial Cancer II
MORAb-003-011  NCT02289950 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer S. Ghamande Donna Wheatley Ovarian Cancer II
NRG-GY006 NCT02466971 
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer S. Ghamande  Kelly Adams Uterine Cervical or Vaginal Cancer II
CONCERTO  (D8488C00001)   NCT02889900 A Single Arm Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib in Women with Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer S. Ghamande  Melissa James  Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  IIb
GOG-0286B   NCT02065687 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer S. Ghamande Kelly Adams Endometrial Cancer II/III
CLOVIS/ CO-338-043 NCT02855944 A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Weekly Paclitaxel in Patients with BRCA-mutant or BRCA-like Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S. Ghamande Donna Wheatley Ovarian, Fallopian Tube, or Primary Peritoneal Cancer III
GOG-3005/ AbbVie   NCT02470585 A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S. Ghamande Melissa James Ovarian, Fallopian Tube, or Primary Peritoneal Cancer III
GOG-3009/ ADXS001-02  NCT02853604 Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV S. Ghamande Kelly Adams Cervical Cancer III
GOG 3012/ PR-30-5017-C   NCT02655016
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy S. Ghamande Kelly Adams Ovarian Cancer III
SOLO-3/ D0816C00010   NCT02282020 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations S. Ghamande Melissa James Ovarian Cancer  III